Search for a trial

1 results

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physicians Choice for Metastatic Triple Negative Breast Cancer (mTNBC) (KEYNOTE-119)

Approved WMORecruitment stopped

The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, Pembrolizumab (MK-3475) compared to other chemotherapy drugs of physician*s choice (which includes Capecitabine, Eribulin, Gemcitabine…

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician*s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) * (KEYNOTE-119)

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physicians Choice for Metastatic Triple Negative Breast Cancer (mTNBC) (KEYNOTE-119)